Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vigil Neuroscience, Inc. - Common Stock (NQ:VIGL)

2.750 +0.190 (+7.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 414,376
Open 2.440
Bid (Size) 2.670 (1)
Ask (Size) 2.750 (10)
Prev. Close 2.560
Today's Range 2.402 - 2.800
52wk Range 1.312 - 6.060
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Thursday's session.
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire

Performance

YTD
+55.4%
+55.4%
1 Month
+55.4%
+55.4%
3 Month
+15.5%
+15.5%
6 Month
-28.9%
-28.9%
1 Year
+0.4%
+0.4%

More News

Read More
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
On Friday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience to Present at Upcoming September Investor Conferences
From Vigil Neuroscience, Inc.
Via GlobeNewswire
VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024
Via InvestorPlace
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Via Benzinga
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
From Vigil Neuroscience, Inc.
Via GlobeNewswire
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
From Vigil Neuroscience, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Vigil Neuroscience, Inc. - Common Stock publicly traded?
Yes, Vigil Neuroscience, Inc. - Common Stock is publicly traded.
What exchange does Vigil Neuroscience, Inc. - Common Stock trade on?
Vigil Neuroscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vigil Neuroscience, Inc. - Common Stock?
The ticker symbol for Vigil Neuroscience, Inc. - Common Stock is VIGL on the Nasdaq Stock Market
What is the current price of Vigil Neuroscience, Inc. - Common Stock?
The current price of Vigil Neuroscience, Inc. - Common Stock is 2.750
When was Vigil Neuroscience, Inc. - Common Stock last traded?
The last trade of Vigil Neuroscience, Inc. - Common Stock was at 05/02/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.